Penicillin V Potassium

Erythema Chronicum Migrans, Scarlet Fever, Anthrax + 21 more

Treatment

2 FDA approvals

20 Active Studies for Penicillin V Potassium

What is Penicillin V Potassium

Phenoxymethylpenicillin

The Generic name of this drug

Treatment Summary

Phenoxymethylpenicillin, also called Penicillin V or Penicillin VK, is an antibiotic that is used to treat mild to moderate infections caused by penicillin-sensitive bacteria. It is also used as a preventive measure in people with certain heart conditions who are undergoing dental or upper respiratory procedures. This medication is an oral form of Penicillin G and has been suggested for use by the American Heart Association and the American Dental Association.

Penicillin V Potassium

is the brand name

Penicillin V Potassium Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Penicillin V Potassium

Phenoxymethylpenicillin

1968

190

Approved as Treatment by the FDA

Phenoxymethylpenicillin, otherwise known as Penicillin V Potassium, is approved by the FDA for 2 uses which include Bacterial Infections and Urinary Tract Infection (UTI) .

Bacterial Infections

Urinary Tract Infection (UTI)

Effectiveness

How Penicillin V Potassium Affects Patients

Phenoxymethylpenicillin is a type of antibiotic that kills bacteria. It works by targeting the bacteria while they are trying to multiply and preventing the bacteria from forming protective cell walls. In lab tests, this drug has been shown to be effective against many types of bacteria, such as staphylococci, streptococci, pneumococci, and certain types of clostridia, actinomyces, listeria, leptospira, neisseria, and treponema.

How Penicillin V Potassium works in the body

Phenoxymethylpenicillin works by disrupting the third and final stage of bacterial cell wall synthesis. It does this by attaching to a special protein within the cell wall, which is necessary for cell wall formation and division. When this protein is blocked, the cell wall is unable to form, leading to cell death.

When to interrupt dosage

The prescribed dosage of Penicillin V Potassium is reliant upon the determined affliction, including Anthrax, Actinomycosis and Erythema Chronicum Migrans. The total amount is contingent upon the manner of administration (e.g. Oropharyngeal or Tablet) depicted in the table below.

Condition

Dosage

Administration

Endocarditis, Bacterial

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Bacterial Infections

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Urinary Tract Infection (UTI)

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Surgical Procedures

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Congenital Heart Defect

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

dental procedures

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Erythema Chronicum Migrans

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Scarlet Fever

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Tonsillitis

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Animal bite

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Anthrax

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Heart Diseases

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Bronchitis

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Streptococcal Pharyngitis

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Heart valve disease

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Vincent Angina

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Actinomycosis

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Respiratory Tract Infections

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

moderate bacterial upper respiratory tract infections

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

prophylaxis of Bacterial endocarditis

, 250.0 mg, 500.0 mg, 125.0 mg/mL, 250.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 300.0 mg, 500000.0 units, 400000.0 units, 800000.0 units, 300.0 mg/mL, 200000.0 units/mL, 500000.0 units/mL, 180.0 mg/mL, 40000.0 units/mL, 250000.0 units/mL, 80000.0 units/mL

, Tablet, Tablet - Oral, Oral, Powder, for solution, Powder, for solution - Oral, Tablet, film coated, Tablet, film coated - Oral, For solution, For solution - Oral, Suspension, Suspension - Oral, Liquid, Liquid - Oral, Capsule - Oral, Capsule, Oropharyngeal, Tablet - Oropharyngeal

Warnings

There are 20 known major drug interactions with Penicillin V Potassium.

Common Penicillin V Potassium Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Phenoxymethylpenicillin.

Chlormadinone

Minor

The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Phenoxymethylpenicillin.

Cloprostenol

Minor

The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Phenoxymethylpenicillin.

Cyproterone acetate

Minor

The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Phenoxymethylpenicillin.

Demegestone

Minor

The therapeutic efficacy of Demegestone can be decreased when used in combination with Phenoxymethylpenicillin.

Penicillin V Potassium Toxicity & Overdose Risk

The lowest toxic dose of penicillin in rats is more than 1040mg/kg. Common side effects include nausea, vomiting, black hairy tongue, and abdominal discomfort. In rare cases, people may experience muscle weakness and seizures. People with severe allergic reactions to penicillin may be at risk of death. If a person overdoses on penicillin, vomiting or stomach pumping should be induced, followed by activated charcoal. It is generally safe to use penicillin while pregnant or breastfeeding.

Penicillin V Potassium Novel Uses: Which Conditions Have a Clinical Trial Featuring Penicillin V Potassium?

68 active clinical trials are currently in progress to assess the ability of Penicillin V Potassium in managing Erythema Chronicum Migrans, Heart Diseases and Tonsillitis.

Condition

Clinical Trials

Trial Phases

Anthrax

1 Actively Recruiting

Phase 2

Actinomycosis

0 Actively Recruiting

Bronchitis

2 Actively Recruiting

Not Applicable

Streptococcal Pharyngitis

0 Actively Recruiting

Heart valve disease

0 Actively Recruiting

dental procedures

0 Actively Recruiting

Vincent Angina

0 Actively Recruiting

Endocarditis, Bacterial

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

moderate Otitis media

0 Actively Recruiting

Surgical Procedures

0 Actively Recruiting

Respiratory Tract Infections

0 Actively Recruiting

Heart Diseases

0 Actively Recruiting

prophylaxis of Bacterial endocarditis

0 Actively Recruiting

moderate bacterial upper respiratory tract infections

0 Actively Recruiting

Erythema Chronicum Migrans

0 Actively Recruiting

Rheumatic Fever

0 Actively Recruiting

Otitis Media

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Congenital Heart Defect

27 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1

Patient Q&A Section about penicillin v potassium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is penicillin V potassium the same as penicillin?

"Penicillin V potassium is an antibiotic that is used to kill bacteria. It is not effective against viral infections such as colds or the flu."

Answered by AI

Is penicillin V potassium good for tooth infection?

"The most common antibiotics that dentists prescribe to treat a tooth infection are penicillin-type drugs, such as amoxicillin and penicillin V potassium."

Answered by AI

Is penicillin V potassium the same as amoxicillin?

"Amoxicillin is a penicillin antibiotic that can be used to treat a wide variety of bacterial infections. However, it cannot be used to treat the flu or common cold, since these are viruses. Penicillin v potassium (Penicillin VK) is a cheap antibiotic that works well for strep infections."

Answered by AI

What is penicillin V potassium 500 mg?

"Penicillin V Potassium is a generic antibiotic that is used to treat various types of bacterial infections. It is commonly prescribed to patients who have pneumonia, scarlet fever, strep infections, staph infections, bacterial infections of the skin, gingivitis, and rheumatic fever."

Answered by AI

Clinical Trials for Penicillin V Potassium

Have you considered Penicillin V Potassium clinical trials?

We made a collection of clinical trials featuring Penicillin V Potassium, we think they might fit your search criteria.
Go to Trials
Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Image of University Health Network in Toronto, Canada.

Empagliflozin for Congenital Heart Disease

18+
All Sexes
Toronto, Canada

Some people are born with a birth defect where they only have one functioning ventricle (lower chamber) in their heart. This condition can be initially managed with a Fontan operation, but there is a risk of developing Fontan Circulatory Failure (FCF) later in life. FCF occurs when the single working heart ventricle is no longer strong enough to pump blood throughout the body. This also means the heart has difficulty supplying oxygen to keep up with the needs of the body. As a result, individuals living with FCF may have some challenges carrying out day to day activities. A heart transplant is currently the only therapeutic option for individuals living with FCF. The investigators are conducting this trial to determine whether a medication called empagliflozin can help these people have a better quality of life.

Phase 3
Waitlist Available

University Health Network

Boehringer Ingelheim

Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Digital Exercise for Congenital Heart Disease

10 - 17
All Sexes
Philadelphia, PA

The goal of this randomized control trial is to learn about physical fitness and exercise habits in children aged 10-17 with the Fontan Circulation through a home-based, digital exercise intervention. The main questions it aims to answer are: * Does a home-based, digital intervention increase physical activity (PA) in youth with the FC compared to enhanced usual care? * Does a home-based, digital intervention increase physical fitness in youth with the FC compared to enhanced usual care? * Do multi-level factors (medical, neurodevelopmental, sociodemographic, neighborhood) impact the effectiveness of the digital intervention? Researchers will compare participants in the enhanced usual care arm to those in the exercise intervention arm to see if the digital intervention is effective. All participants will wear a PA tracker for 12 months and complete testing at baseline, 6 months, and 12 months. In addition, participants in the exercise intervention arm will complete a 6-month exercise intervention with the following components: * aerobic exercise * resistance exercise * engagement strategies

Recruiting
Has No Placebo

Children's Hospital of Philadelphia

Elizabeth Goldmuntz, MD

Image of MS CHONY inpatient units, including regular floor units, stepdown units, and ICU in New York, United States.

Propranolol for Chylothorax

7 - 18
All Sexes
New York, NY

Postoperative chylothorax is a serious complication after open heart surgery for pediatric patients with congenital heart disease (CHD). While it was thought to be mechanical injury to the thoracic duct, recent research demonstrated that there are intrinsically abnormal lung lymphatics in CHD patients, and after open heart surgery, the fluid shifts that occur overwhelms these abnormal lung lymphatics. As a result, postoperative chylothorax occurs. Propranolol has been found to be helpful in resolving postoperative chylothorax very quickly (9 days) in a subset of postoperative chylothorax patients (60%). However, it is not known why some patients respond and some do not. The investigators hypothesize that propranolol is safe to use in this patient population, and that certain clinical factors will predict propranolol response, but more importantly, some clinical factors can be optimize to allow more patients with postoperative chylothorax to respond to and benefit from propranolol. In order to improve the understanding of how propranolol works and to maximize benefit to patients, the investigators propose to perform a prospective, randomized, double-blind clinical trial to learn how to best use propranolol in patients with postoperative chylothorax.

Phase 1 & 2
Recruiting

MS CHONY inpatient units, including regular floor units, stepdown units, and ICU (+1 Sites)

June Wu, MD

Have you considered Penicillin V Potassium clinical trials?

We made a collection of clinical trials featuring Penicillin V Potassium, we think they might fit your search criteria.
Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

Phase 4
Recruiting

Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)

Have you considered Penicillin V Potassium clinical trials?

We made a collection of clinical trials featuring Penicillin V Potassium, we think they might fit your search criteria.
Go to Trials